Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review Publisher



Fallahi MS¹ ; Zerangian N² ; Ghorbani A³ ; Erabi G⁴ ; Shirali M¹ ; Shabani E⁵ ; Rommasi F^{6, 7} ; Najafabadi MM⁸ ; Karbasi S⁸ ; Toutounchian S¹ ; Ahangarsirous R⁹ ; Motaghy A¹⁰ ; Heidari M³ ; Deravi N¹¹
Source: Current Cancer Therapy Reviews Published:2024

Abstract

Non-Hodgkin lymphoma (NHL) occurs in the lymphatic system because of lymphocytes tumor. This type of tumor has a high death rate among patients. In recent years, a lot of progress has been made based on understanding its exact biology; several treatment methods have been developed. Many patients are cured by a combination of different chemotherapies, despite their toxic effects. In recent years, despite various studies on monoclonal antibodies for non-Hodgkin lymphoma, there have been no narrative articles in this field. Therefore, combining monoclonal antibodies with chemotherapy is successful as they reduce the toxic side effects of chemotherapies. These antibodies can target specific cellular pathways of the immune system leading to limitation of cancer progression. In this article, various types of monoclonal antibodies, their underlying mechanisms of action, as well as their effects on patients with different phases and types of Non-Hodgkin lymphoma have been reviewed for a better understanding. © 2024 Bentham Science Publishers.